Anti-EGFR-based therapies don't increase survival in patients with these mutations
Thursday, January 6, 2011 (Last Updated: 01/10/2011)
THURSDAY, Jan. 6 (HealthDay News) -- Individuals with KRAS mutations treated with anti-epidermal growth factor receptor (anti-EGFR)-based therapy for advanced colorectal cancer (CRC) appear to experience reduced survival and higher treatment failure rates, according to a review published in the Jan. 4 issue of the Annals of Internal Medicine.
Issa J. Dahabreh, M.D., of Tufts Medical Center in Boston, and colleagues conducted a systematic review and analysis of published studies regarding the role of KRAS mutations in the prediction of survival or treatment failure in patients treated with anti-EGFR-based therapy for metastatic CRC.
The researchers found no significant improvement in overall or progression-free survival for KRAS-positive patients taking anti-EGFR-based treatment, although evidence did favor the therapy for KRAS wild-type patients. A meta-analysis of 22 studies suggested sensitivity and specificity at 0.49 and 0.93, respectively, in KRAS mutations for predicting lack of response to anti-EGFR-based therapy.
"KRAS mutations are consistently associated with reduced overall and progression-free survival and increased treatment failure rates among patients with advanced CRC treated with anti-EGFR antibodies," the authors write.
Copyright © 2010 HealthDay. All rights reserved.